S H Kelkar & Company Ltd IPO Message Board (Page 8)

stop payment karau k nahi.............?
please advise

ha

Dont Stop Payment .... It will Give 2000 Rupess Per Form

S H KELKAR PREMIUM PLZ:

Any news regarding R E C Tax Free Bonds ?

Yes this is saata game.

FINAL CHE STONG BUYER TO CHEQ STOP PAMENT NA KARU

Strong buyer com 25-27.

S H KELKAR PREMIUM PLZ:

Final subscription tally of SHK IPO (excluding Anchor Investors) is 27.08 times over subscription - QIBs 25.55 times, HNI 87.38 times and Retail 2.14 times.

Premium 4 Rs sellllllerrrr
Sellllll fast
Lossssssssssssss
Fair value 150

Cancel allotment

PINKYBEN SHKELKAR MA RS STOP KARU : PLZ YES & NO

Why Loss????
when GMP = 21.50

ALLOTMENT RATIO PLZ MEMBERS

Premium 27 buyerrrrrrrrrrreee

Kelkar ka premium kya hai I have 3000 shares

Share premium fixed by company may be cancelled by SEBI/Fin.Ministry, GoI. IPO fully subscribed in support of FII and Institutes and Mutual Funds only. In the good old days, its predecessor CCI was playing an important role to fix premium in IPO price, and more importantly no premium was allowed to be collected on IPOs. It is hoped that old system may be implemented immediately. Retail investors always loss their money by high premium.

There are signs of a revival in the primary market which was lying dormant in the past couple of years. With the market sentiment turning bullish following a change of guard at the centre, corporates are dusting off their IPO plans. India''s seventh largest pharmaceutical company Mumbai-headquartered Alkem Labs is exploring options for a blockbuster listing in FY15 , three sources familiar with the development told ET NOW.



" Alkem Labs is considering plans to launch an IPO to raise between Rs 3000 crores to Rs 4000 crores which if finalised could potentially be one of the biggest offerings in the pharma space in a long time. The likely timeline for the IPO is around the second half of FY15 and a proposed equity dilution of around 25% would value the company anywhere between Rs 12000-Rs16000 crore rupees. Merchant bankers are learnt to have been shortlisted by the company," said one of the three sources cited above without elaborating further.

80% of the company''s revenues currently come from domestic operations and now it''s main focus is on the US market. " Alkem Labs is scheduled to have its board meeting in a few weeks during which the final nod for the IPO will be sought. The company is also on the prowl for acquisitions in the US," said another source familiar with the company''s plans.

"There is a growing domestic pharma market and a very large global market to penetrate even further. Large Indian pharma companies have global competence and we have a near perfect ecosystem in India to capitalise further in this sector. The market appetite remains strong to receive offerings from pharma, consumer and financial services businesses," says Ashutosh Maheshwari, CEO, Motilal Oswal Investment Advisors.

In an email response to a query from ET NOW, Alkem Labs said , " We would like to clarify that whilst, the company keeps evaluating various options including those for potential fund raising proposals from time to time, we have not yet finalised any concrete plans for an IPO at this time. We have no further comments on this matter at this stage. "

Alkem Laboratories, which was founded in 1974 had consolidated annual revenues of Rs 3100 crores and consolidated annual profits stood of around Rs 620 crores for FY 13-14. It has 14 brands in the top 300 formulation brands in the country with its blockbuster antibiotic Taxim contributing around Rs 170-Rs 180 crores to annual revenues.

The company covers both acute and chronic therapeutic segments and its products are marketed in 35 countries worldwide. Alkem Labs also has interests in the health food market and has up the world''s largest sucralose ( artificial sweetener) producing unit in India according to the company''s website.

strong bayarr
35...38 wowwwwww

Koi 40 rs mein purchase karega

Maine SHK IPO mein one lot @173 k liye apply kiya hai. Koi bata sakta hai ki mujhe shares allot ho sakta hai ya nahi.

BACHI GAYO BHAI 4 sellllllerrrr

Thanks 2 all 4 reply.

Can I get information of Alkem weather is it apply or not n company''s details

Plz allotment ratio menbe

Upcoming ipo
Alkem Laboratories
Issue price 1435-1465
Lot size 10

Issue size 1865 cr
Face Value Rs 2 each

Issue opens 14th Nov
Issue closes 16th Nov

Morgan Stanley India

Plz allotment ratio PInkyben:

CCD - The issue with price band of
Rs313/328 got poor response in all categories except QIB. Still the price
band is fixed at upper price band of Rs328. It should be noted that QIB
had made bids at Rs.322. So they need to pay crores of rupees towards
difference. As a result, the listing could be around Rs320-330. It may
slip in discount after listing

Kelkar - It may get listed on November 17. It may get listed around
Rs200 and then go up to Rs210 or 220.

Indigo- The issue may get listed on November 16 as the market will
be closed on November 11 and 12 due to Diwali holidays. The stock
may get listed around Rs780-785 and cross Rs800 level after listing.
The circuit limit is 20% so high volatility is expected.